

Subject Index

9-Aminocamptothecin (9-AC). *See also*

- Camptothecins
 - anti-colon cancer activity of, 258
 - antitumor activity of, 10-11, 181-186
 - order of effectiveness, 181, 186
 - in xenograft systems, 181-182
 - blood chemistry of, 29-31
 - clinical pharmacology of, 237-239, 324-326
 - clinical responses to, 252-254
 - clinical trials of, 10-11, 231-233, 247-248
 - clinical efficacy, 251-252
 - 21-day continuous infusion, 235-236
 - drug formulation, 233
 - 72-hour continuous infusion, 233-237
 - oral delivery, 237
 - patient characteristics, 250
 - pharmacokinetics, 252
 - toxicity, 250-251
 - weekly 120-hour continuous infusion, 236
 - perspectives, 242-243
 - pharmacokinetic/pharmacodynamic studies of, 315-317
 - preclinical trials, 231-233
 - next generation, 239-241
 - radiation therapy enhancement by, 312-314
- Antitumor activity. *See under* specific agents
- Apoptosis
- anti-topo drugs and, 36
 - and camptothecin resistance, 63-64
 - CPT-induced, 93-96
 - concentration dependence of, 97-98
 - in HL-60 cells, 104-109
 - detection of
 - by DNA content changes, 103
 - methods for, 101-102
 - by regulatory proteins presence, 149-151
 - in situ*, 103-104
 - DNA loss in, 104-109
 - in drug-resistant malignant cells, 143-153
 - 9-NC-induced, 143-145
 - in oncology, 102
 - p53 and, 64
 - proteins regulating, 149-153
 - and resistant/sensitive leukemia assay, 136, 138
 - TPT-induced, 102, 106-109, 136-138

Breast cancer

- CPT-11 activity against, 282, 288, 292-293
 - TPT activity against, 268
- ## Camptotheca acuminata
- fractionation of, 2-5
 - phytochemical screening and, 1
- ## Camptothecin (CPT)
- analogs of. *See also* Camptothecins; specific analogs
 - biological activity of, 6
 - clinical trials of, 9-11
 - structure activity relationship studies, 7-8
 - antitumor activity of, 6-7, 20-22
 - apoptosis induction by, 93-99, 101-102
 - cell cycle effects of
 - and apoptosis, 93-96, 99
 - cell type and, 97-98
 - concentration dependence of, 97-98
 - and DNA transcription, 96-97
 - clinical studies of, 6-7, 224-225, 229-230
 - antitumor activity, 226-227
 - CPT formulation, 225-226
 - patient characteristics, 226
 - pharmacokinetics, 227-228
 - toxicity, 227
 - cytotoxicity of
 - anti-topo drugs and, 35-37
 - DNA relaxation and, 46-47
 - DNA synthesis and, 36, 129
 - fork collision model for, 44-46
 - mechanisms of, 49
 - PLDBs and, 74-89
 - replication-independent, 44-46
 - selectivity of, 98-99
 - S-phase specificity of, 44, 102
 - topo I multi-ubiquitination and, 48
 - discovery of, 2
 - and DNA damage, 44-49
 - pharmacokinetics of, 157-158
 - distribution in tumor-bearing mice, 158-159
 - form conversion rate, 184-186
 - lactone/salt equilibrium, 159-160
 - physical properties of, 5
 - resistance to
 - cell lines with, 75-76
 - PLDBs and, 76-82
 - topo I complexes and, 60-66
 - topo I down-regulation and, 82-89
 - sensitivity to
 - topo complexes and, 32-33

- topo mutations and, 33-35, 63
 - structure of, 5-6
 - synthesis of, 7
 - via radical transannulation, 310-311
 - and topo I activity, 33
 - and topo I catalysis, 50-59
 - and topo I ubiquitination, 48-49
 - Camptothecin-11 (CPT-11). *See also* Camptothecins
 - antitumor activity of, 13, 24-26, 173-178
 - against cervical cancer, 277
 - against colorectal cancer, 257-258
 - intravenously administered, 175-176
 - against multidrug-resistant tumors, 177
 - orally administered, 176
 - against previously untreated colorectal cancer, 276-277
 - against recurrent colorectal cancer, 274-276
 - clinical trials of, 9-11
 - current U.S. status of, 272, 280
 - Phase I single agent trials, 272-274
 - Phase I trial issues, 279
 - Phase II single agent trials, 274
 - Phase III trial issues, 279-280
 - European Phase I trials, 282-283, 289
 - antitumor activity in, 285
 - optimum administration schedule, 285-286
 - pharmacokinetic studies, 286
 - toxicity, 283-285
 - European Phase II trials, 286-287
 - breast cancer, 288
 - cancer of the cervix, 288
 - colorectal cancer, 287, 289
 - NSCLC, 288
 - pancreatic cancer, 287
 - SCLC, 288
 - European preclinical trials, 282
 - Japanese Phase I trials, 301
 - in advanced NSCLC, 295
 - of CPT-11, 292-293
 - of CPT-11-cisplatin combination, 293-294
 - of CPT-11-cisplatin-vindesine combination, 295
 - of CPT-11-etoposide combination, 295
 - in NSCLC, 296-297
 - Japanese Phase I/II trials
 - of CPT-11-cisplatin-thoracic radiation therapy, 297-298
 - pharmacokinetic studies, 299-300
 - in stage III NSCLC, 298
 - Japanese Phase II trials, 301-302
 - of CPT-11-cisplatin combination, 293-294
 - of CPT-11-etoposide combination, 295-296
 - in NSCLC, 294
 - in SCLC, 294
 - Japanese Phase III trials, 298-299
 - multiagent trials, 277-278
 - NSCLC, 278
 - pharmacokinetics of, 177-178
 - antitumoral responses, 168-169
 - dose influence on, 166-167
 - patient characteristics influence on, 167-168
 - review of, 164-169
 - side effects, 168
 - treatment frequency influence on, 166
 - in tumor-bearing mice, 173-178
 - in vitro* specificity, 174
 - in vivo* efficacy, 174-177
 - resistance to, 62
 - schedule-dependent efficacy of, 188-190
 - dose intensification effect, 191-192, 194-199
 - extended therapy duration effect, 193-194, 196-199
 - systemic exposure, 194-195
 - second generation synthesis of, 310-311
 - SN-38 active ingredient of, 10
 - synthesis of, 13-26
- Camptothecins
- antitumor activity of, 2
 - against colon cancer, 257
 - preclinical rationale for, 256-257
 - and apoptosis, 93-99
 - biological activity of, 6-10
 - bloodchemistry of, 29-31
 - Camptotheca acuminata* fractionation and, 2-5
 - cellular resistance to, 60-61, 65-66
 - apoptosis role in, 63-64
 - development of lines with, 75-76
 - DNA repair and, 64-65
 - with normal cleavable complexes, 63-65
 - PLDBs and, 74, 80-82
 - with reduced cleavable complexes, 61-63
 - topo I down-regulation and, 82-89
 - topo I levels and, 62-63
 - topo I mutations and, 63
- clinical development issues, 217
- cytokine dose-intensification, 217-218
 - pharmacodynamic response determinants, 218
 - pharmacokinetics and scheduling, 217
- clinical response determinants of, 259-261
- clinical studies of, 224-225, 228-230
 - antitumor activity, 226-227
 - patient characteristics and, 226

- pharmacokinetics, 227-228
- toxicity, 227
- and CNS xenograft treatment, 210-212
- cytotoxicity of
 - DNA relaxation and, 46-47
 - mechanism of action of, 44-49
 - PLDBs and, 80-82
 - replication collision model for, 44-46
 - S-phase specificity of, 44
 - topo I down-regulation and, 82, 84-85
 - topo I multi-ubiquitination and, 48
- and DNA damage, 46-47, 50-59, 129
- early clinical trial of, 6-7
- pharmacokinetics of, 164-169
 - orally administered, 157-162, 176
 - in tumor-bearing mice, 173-178
- second generation synthesis of, 310-311
- sensitivity to
 - DNA elongation and, 308-309
 - factors affecting, 128-129
- structure-activity-relationship of, 8-9
- structures of, 5-6
- synthesis of, 7, 9, 13-26
- therapeutic indications of
 - for hematologic neoplasias, 216-217
 - for NHL, 216-217
 - for NSCLC, 215-216
 - for ovarian cancer, 213-214
 - for SCLC, 216
 - for uterine cervical cancer, 214-215
- topo inhibition by, 7, 9
- treatment protocols for tumor
 - xenografts, 181-186
- treatment protocols with, 181-186
 - drugs used, 182-184
 - pharmacokinetics, 184-186
 - xenograft systems, 181-182
- Cervical cancer
 - clinical trials with CPTs, 214-215
 - CPT-II activity against, 288, 292-293
 - Phase II trials in, 277
- Colorectal cancer
 - 9-AC activity against, 258
 - camptothecins
 - clinical activity against, 257
 - rationale for, 256-257
 - CPT-II activity against, 282, 287, 292-293
 - Phase II trials, 274-276
 - topo I inhibitors in, 256-261
 - TPT activity against, 258
- CPT. *See* Camptothecin
- D**NA
 - apoptosis-associated loss of, 104-109
 - cleavage of
 - topo I-mediated, 50-52
 - topo I mutations and, 111-112, 116-121
 - CPT-induced relaxation of, 46-47
 - CPT selective toxicity for, 98-99
 - damage to
 - anti-topo agents and, 35-37
 - CPT and, 44-49, 57-61
 - mechanisms of, 44-49
 - PLDBs and, 74-89
 - ligation of
 - CPT-mediated inhibition of, 56-58
 - topo I catalysis and, 50-56
 - topo I mutations and, 121-123
 - relaxation
 - camptothecins inhibition of, 10
 - mutant topo I inhibition of, 115-116
 - repair of
 - and camptothecin resistance, 64-65
 - and camptothecin sensitivity, 308-309
 - topo I and, 37-40, 50-59
 - topo II and, 33-34
- G**II47211C
 - antitumor activity of, 205-206
 - as new CPT analog, 202-203
 - criteria for, 203-205
 - topo I inhibition by, 205
 - Phase I clinical trials, 208-209
 - preclinical research on, 206-207
 - and tumor cell cytotoxicity, 205
 - in vivo* efficacy of, 206
- 10-**H**ydroxycamptothecin. *See also* SN-38
 - antitumor activity of, 6, 20-23, 25-26
 - synthesis of, 7, 9-10, 14-20
- I**rinotecan. *See* Camptothecin-II
- L**eukemia
 - camptothecins activity against, 2-5
 - cell topo I levels in, 130-131
 - TPT-combination efficacy in, 138-140
 - TPT-sensitivity of, 138-140
 - cell topo I content, 133-135
 - factors in, 128-130
 - leukemia type, 134
- N**HL. *See* Non-Hodgkins lymphoma
- 9-Nitrocamptothecin (9-NC)
 - antitumor activity of, 181-186
 - order of effectiveness of, 181, 186
 - in xenograft systems, 181-182
 - apoptosis induction by, 143-153
 - clinical efficacy of
 - concentration dependence of, 143
 - suramin-enhanced, 144-153

- clinical studies of, 224–225, 229–230
 antitumor activity, 226–227
 9-NC formulation, 225–226
 patient characteristics, 226
 pharmacokinetics, 227–228
 toxicity, 227
- pharmacokinetic studies of, 227–228
 effect of administration route, 158–159
 form conversion rate, 184–186
 lactone/salt equilibrium, 159–160
 orally administered, 157–158
 suramin-enhanced cytotoxicity of, 143–145, 146–153
 treatment protocols, 181–186
- Non-Hodgkins lymphoma (NHL)
 clinical trials with CPTs, 216–217
 CPT-11 for, 292–293
- Non-small cell lung cancer (NSCLC)
 clinical trials with CPTs, 215–216
 CPT-11 activity against, 282, 288, 292–293
 CPT-11-cisplatin activity against, 294
 CPT-11-cisplatin-vindesine activity against, 295
 CPT-11-etoposide activity against, 296–297
 multiagent trials in, 278
 Phase I trials in, 294–296
 Phase II trials in, 294
 TPT activity against, 267–268
- NSCLC. *See* Non-small cell lung cancer
- O**varian cancer
 clinical trials with CPTs, 213–214
 CPT-11 activity against, 282, 292–293
 TPT activity against, 265–266
- P**ancreatic cancer, CPT-11 activity against, 287
- Pharmacokinetics
 of camptothecins, 184–186
 orally administered, 157–162
 of CPT-11
 intravenously administered, 175–176
 review of, 164–169
 in tumor-bearing mice, 173–178
 of SN-38, 177–178
- PLDBs. *See* Protein-linked DNA breaks
- Protein-linked DNA breaks (PLDBs)
 CPT-induced, 74
 formation of
 replication fork collisions and, 74–75
 steps after, 80–82
 steps prior to, 76, 78–80
- S**CLC. *See* Small cell lung cancer
- Small cell lung cancer (SCLC)
 CPT-11 activity against, 288, 292–293
 CPT-11-cisplatin combination for, 294
 Phase II trials in, 294
 therapeutic indications for
 camptothecins in, 216
 TPT activity against, 266–267
- SN-38. *See also* Camptothecins
 antitumor activity of, 20–26
 blood chemistry of, 29–31
 as CPT-11 active ingredient, 10
 pharmacokinetics of, 177–178
 patient characteristics influence on, 167–168
 side effects, 168
 resistance to, 62
 systemic exposure of, 194–195, 197–198
 TI of, 20–22
 water-soluble prodrugs of, 19–20
- Suramin
 and 9-NC efficacy, 144–148
 9-NC-resistant cell sensitivity to, 148–149
- T**herapeutic index (TI)
 of camptothecins, 21–22
 of SN-38, 20–22
- TI. *See* Therapeutic index
- Topo I. *See* Topoisomerase I
- Topo II. *See* Topoisomerase II
- Topoisomerase I (Topo I)
 catalysis
 CPT effect on, 57–59
 of DNA cleavage, 50–59
 of DNA ligation, 53–56
 down-regulation of
 and CPT resistance, 74, 82, 84–85
in vivo analysis of, 85, 87–89
 drugs targeting, 33
 inhibition of
 by CPT, 33–35
 and DNA replication, 93–95
 by G1147211C, 202–209
 inhibitors of
 in colon cancer management, 256–261
 cytotoxic efficacy of, 306–307
 and DNA damage, 37–40
 in systemic sclerosis treatment, 318–320
 levels of
 in leukemia cells, 130–131
 in normal lymphohematopoietic cells, 130–131
 in tumor cells, 60
 multi-ubiquitination of, 48
 mutations of
 and DNA binding, 121–123
 and DNA cleavage, 111–112

- and impaired DNA cleavage, 116-121
 - increased drug sensitivity of, 122-123
 - interactions with CPT, 123-126
 - and plasmid relaxation activity, 115-116
 - and phosphorylation-reduced CPT sensitivity, 321-322
 - Topoisomerase II (Topo II)
 - CPT inhibition of, 32
 - and DNA repair, 33-34
 - and drug sensitivity/resistance, 32
 - drugs targeting, 32-33
 - cell-killing mechanisms of, 35-37
 - sensitivity/resistance genes and, 33-35
 - yeast studies of, 32-40
 - inhibitor combinations, cytotoxic efficacy of, 306-307
 - inhibitors of. *See also* Camptothecins
 - cytotoxic efficacy of, 306-307
 - Topoisomerases
 - anticancer drugs and, 32-33
 - cell-killing mechanisms of, 35-37
 - and DNA repair, 37-40, 50-59
 - drugs targeting, 32-33
 - and apoptosis, 36
 - and CPT cytotoxicity, 35-37
 - and sensitivity/resistance, 33-35
 - yeast studies of, 32-40
 - inhibition of, 7, 9
 - inhibitors of. *See also* Camptothecins
 - levels in tumors, 60
 - mutations in
 - and CPT interaction, 111-112, 115-126
 - and drug sensitivity/resistance, 33-35
 - Topotecan (TPT)
 - anti-colon cancer activity of, 258, 268
 - apoptosis induction by, 102, 106-109, 136-138
 - clinical studies of, 9-11, 264, 269
 - in combination therapy, 268
 - early clinical data from, 264
 - in NSCLC and other tumor types, 267-268
 - by oral administration, 268
 - in ovarian cancer, 265-266, 269
 - Phase I combination studies, 264
 - Phase I single-agent study, 131-132
 - in SCLC, 266-267, 269
 - treatment schedules and regimens, 268
 - in combination therapy, 264, 268
 - against HL-60 cells, 138-140
 - prospects for, 140
 - schedule-dependent efficacy of, 188-190
 - second generation synthesis of, 310-311
 - sensitivity to, 128-130
 - assay of, 136-137
 - factors affecting, 132-135
 - of leukemia cell lines, 138-140
- TPT. *See* Topotecan